KR20240026939A - 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 - Google Patents
세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 Download PDFInfo
- Publication number
- KR20240026939A KR20240026939A KR1020237044476A KR20237044476A KR20240026939A KR 20240026939 A KR20240026939 A KR 20240026939A KR 1020237044476 A KR1020237044476 A KR 1020237044476A KR 20237044476 A KR20237044476 A KR 20237044476A KR 20240026939 A KR20240026939 A KR 20240026939A
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- alkyl
- trans
- cyclohexyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163215243P | 2021-06-25 | 2021-06-25 | |
| US63/215,243 | 2021-06-25 | ||
| PCT/US2022/034921 WO2022272074A1 (en) | 2021-06-25 | 2022-06-24 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240026939A true KR20240026939A (ko) | 2024-02-29 |
Family
ID=84543920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237044476A Pending KR20240026939A (ko) | 2021-06-25 | 2022-06-24 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240368118A1 (https=) |
| EP (1) | EP4359407A4 (https=) |
| JP (1) | JP2024526191A (https=) |
| KR (1) | KR20240026939A (https=) |
| CN (1) | CN117561249A (https=) |
| WO (1) | WO2022272074A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4692061A1 (en) * | 2023-03-29 | 2026-02-11 | Aevis Bio, Inc. | Low-molecular-weight compound having cereblon-binding activity, and use thereof |
| AU2024298923A1 (en) | 2023-07-25 | 2026-01-22 | Monte Rosa Therapeutics Ag | Substituted piperidinediones for targeted protein degradation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| TWI726969B (zh) * | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| IL312367A (en) * | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| EP3658548A1 (en) * | 2017-07-28 | 2020-06-03 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN113453681B (zh) * | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| CN114521196A (zh) * | 2019-09-16 | 2022-05-20 | 诺华股份有限公司 | 双官能团降解剂及其使用方法 |
| KR20230027066A (ko) * | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
-
2022
- 2022-06-24 CN CN202280044021.6A patent/CN117561249A/zh active Pending
- 2022-06-24 JP JP2023579304A patent/JP2024526191A/ja active Pending
- 2022-06-24 WO PCT/US2022/034921 patent/WO2022272074A1/en not_active Ceased
- 2022-06-24 KR KR1020237044476A patent/KR20240026939A/ko active Pending
- 2022-06-24 EP EP22829394.0A patent/EP4359407A4/en active Pending
- 2022-06-24 US US18/573,723 patent/US20240368118A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4359407A1 (en) | 2024-05-01 |
| US20240368118A1 (en) | 2024-11-07 |
| CN117561249A (zh) | 2024-02-13 |
| WO2022272074A1 (en) | 2022-12-29 |
| JP2024526191A (ja) | 2024-07-17 |
| EP4359407A4 (en) | 2025-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4171568B1 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| US12103920B2 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| EP4171567B1 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| KR20240026939A (ko) | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 | |
| KR20240025613A (ko) | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 | |
| US20250100995A1 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| HK40091356A (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| HK40091356B (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| HK40091357B (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| HK40091357A (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231222 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250624 Comment text: Request for Examination of Application |